Background/aim: Head and neck cancer (HNC) patients are usually diagnosed with advanced disease and multimodality therapies are required, as well as prognostic biomarkers to predict their response and assess survival. In this study, we aimed to evaluate the ability and clinical significance of the immune biomarker sIL-2R in HNC patients, to assess therapy response and prognosis.
Materials And Methods: We evaluated 328 blood samples from 145 head and neck cancer patients (HNC) from several subgroups: 84 larynx carcinomas pre- and 39 post-therapy, 46 oral cavity carcinomas pre- and 29 post-therapy, 12 nasopharynx carcinomas, 16 parotid and other salivary gland carcinoma patients. The control group included 45 healthy subjects. Serum sIL-2R levels were evaluated by ELISA assays and correlated to disease stage, lymph nodes, response to therapy, survival and cancer differentiation.
Results: Significantly higher sIL-2R levels were recorded in all HNC patients, as opposed to controls, in advanced versus early-stage disease that decreased following therapy. sIL-2R distinguished best, in comparison to other tumor markers, between HNC patients and controls. Survival was strongly associated to lower sIL-2R levels in patients entering the study.
Conclusion: sIL-2R is a sensitive immune marker for HNC patients. Its levels correlate to disease stage, assess response to therapy and are predictive of recurrence or better survival. We suggest, therefore, using sIL-2R as a reliable prognostic marker in HNC patients as a single marker, or in a combined panel of biomarkers.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Aberrant DNA methylation of EDNRB, MGMT and TIMP3 gene promoters in saliva of head and neck carcinoma patients as a diagnostic tool.
Mol Biol Rep
January 2025
Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, 342005, India.
Background: Differential DNA methylation in the promoter region of tumour suppressor genes leads to gene function silencing.
Materials And Methods: In this study, we aimed to evaluate the salivary promoter methylation of EDNRB, MGMT and TIMP3 genes in H&NC patients (n = 100), premalignant lesions patients (n = 25) and healthy controls (n = 50). Blood and saliva samples were collected from all three groups and 20 concomitant tumour tissues were collected from the H&NC patients.
[Pre-implementation of electronic patient-reported outcomes at reference centers for head and neck oncology : A roadmap towards patient-centered digitalization].
HNO
January 2025
Universitätsklinik für Hals‑, Nasen- und Ohrenheilkunde, Kopf- und Halschirurgie Innsbruck, Medizinische Universität Innsbruck, Anichstr. 35, 6020, Innsbruck, Österreich.
Background: Electronically captured patient reports (electronic patient-reported outcomes, ePROs) are digital questionnaires filled out by cancer patients. Despite indications of improved clinical care, the integration of ePROs into clinical head and neck oncology is uncharted territory.
Objective: This work outlines the implementation process for ePROs at the University Hospital for Otorhinolaryngology at the Medical University of Innsbruck (ENT Innsbruck).
Feasibility of a comprehensive supervised exercise program during and after treatment of head and neck cancer: a mixed-methods study.
Support Care Cancer
January 2025
Laboratory of Experimental Radiotherapy, Department of Oncology, University of Leuven, Louvain, Belgium.
Purpose: This study evaluates the feasibility of a comprehensive supervised exercise program (CSEP) for head and neck cancer (HNC) patients during and after (chemo)radiotherapy, integrating quantitative and qualitative data to identify participation barriers and facilitators.
Methods: To investigate the feasibility of the CSEP, a mixed-method study was performed. For the quantitative part, first, adherence to and safety of the CSEP were considered as quantitative feasibility outcome measures.
Efficacy and Safety of Short Intravenous Hydration for Preventing Nephrotoxicity From High-Dose Cisplatin: A Randomized, Open-Label, Phase II Trial.
JCO Glob Oncol
January 2025
Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand.
Purpose: The use of short hydration (SH) to prevent cisplatin-induced nephrotoxicity lacks substantive prospective evaluation. The aim of this study was to evaluate the safety and efficacy of SH, including those with head and neck cancer (HNC) who are at higher risks of mucositis that causes diminished oral intake.
Methods: This phase II randomized noncomparative trial included patients with cancer who were scheduled to receive high-dose cisplatin (≥60 mg/m) in combination with another chemotherapy or concurrently with radiotherapy.
Nasopharyngeal, tongue and laryngeal cancer in Southern Ethiopia: a seven-year retrospective cross-sectional review.
Ecancermedicalscience
October 2024
Department of Midwifery, College of Medicine and Health Sciences, Hawassa University, 1560 Hawassa, Ethiopia.
Background: The burden of cancer is increasing globally and is having a negative impact on people's physical, mental and financial health. On the other hand, developing countries are not progressing to prevent the disease at the same rate as the disease burden increases. The development of strategies for cancer prevention, control and treatment that contribute to the community's improved health requires knowledge of cancer epidemiologic data.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!